EGPI Firecreek Inc. Trading +33%

Orlando, FL 11/28/11 (StreetBeat) -- EGPI Firecreek, Inc. (OTCBB: EFIR.OB) announced through its wholly owned subsidiary Energy Producers, Inc. (EPI) that, having arranged almost $500K in finance, it has moved forward on plans to commence with work programs in December on its #18-1 well and Craward #2 well bore for its interests-owned J.B. Tubb Leasehold Estate, located in the Amoco Crawar Field, Ward County, Texas (12 miles west of Monahans and 30 miles west of Odessa). The work programs will stimulate oil and gas production to what operations and management believes will be good commercial levels following the high pressure Frac techniques. Estimates expected range from 20 to 40 BOPD per well increase in production. In preparation for the December work programs Success Oil Co., EPI's operations for Tubb and Co-Partner for the field will commence site preparation to accommodate for the Frac operations.

As previously reported, the Company continues to explore various options for deploying new work programs and further development for its interests owned J.B. Tubb Leasehold Estate and is aggressively pursuing proposed $8.5 million financing in capital expenditures for the Tubb drilling and completion programs for up to seven wells. Drilling programs are initially being pursued in the South 40 acreage of the J.B. Tubb for the Ellenburger formation to 8,400 ft; Wolfcamp formation at 6,200 ft; Waddell formation at 7,700-7,900 ft. depth. Other available drilling formations at the site include good potentials for Tubb at 4,500 ft; Devonian at 6,700 ft, Glorieta at 3,800 ft; and Upper Clearfork at 4,100-4,550 ft. depth.

Dennis Alexander , EGPI's CEO, stated, "We are excited in accomplishing finance arrangements for these scheduled work programs / Frac procedures especially in current economic times. Further these efforts will carry us forward in maintaining our plan for continued growth and building for our future operations."

About EGPI Firecreek, Inc.
EGPI Firecreek, Inc.'s business and acquisition strategy is focused on oil and gas production with an emphasis on acquiring existing fields with proven reserves, the rehabilitation of potentially high throughput oilfields, resource properties and inventories, through its wholly owned subsidiary Energy Producers, Inc. (Energy Producers) and for oil and gas servicing business through its wholly owned subsidiary Chanwest Resources, LLC. EGPI Firecreek, Inc. is also looking to expand into alternative energy sources as well as industries in the energy field.

StreetBeat Disclaimer

Distributed by Viestly

Tekmira Pharmaceuticals Receives FDA Approval, Trading +14%

Palm Beach, FL 11/28/11 (StreetBeat) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today that its Investigational New Drug (IND) application for TKM-Ebola has been approved by the United States Food and Drug Administration (FDA) allowing Tekmira to initiate a Phase 1 clinical trial.

Tekmira is developing TKM-Ebola, a systemically delivered RNAi therapeutic that utilizes Tekmira's lipid nanoparticle (LNP) delivery technology, for the treatment of Ebola virus infection. There are no approved treatments for Ebola or other hemorrhagic fever viruses. Preclinical studies published in the medical journal The Lancet demonstrated that when small interfering RNA (siRNA) targeting the Ebola virus and delivered by Tekmira's LNP technology were used to treat previously infected non-human primates, the result was 100 percent protection from an otherwise lethal dose of Zaire Ebola virus (Geisbert et al., The Lancet, Vol 375, May 29, 2010).

"We are pleased to have received the FDA's approval of our TKM-Ebola IND. With this approval, we remain on track to achieve another significant milestone for the company by initiating the Phase 1 clinical trial of this product in early 2012," said Dr. Mark J. Murray, Tekmira's President and CEO.

"TKM-Ebola is being developed under a $140 million contract awarded to us by the U.S. Government's Transformational Medical Technologies (TMT) Program. We look forward to continuing this successful collaboration to drive the TKM-Ebola program forward in clinical development," added Dr. Murray.

In addition to the TKM-Ebola product development work sponsored by TMT, this program has supported further development of Tekmira's LNP technology, resulting in a successful 100-fold scale up of the LNP manufacturing process as well as the development of lyophilization (freeze drying) processes while maintaining key LNP product characteristics. These advances will support the late stage clinical development and commercialization of TKM-Ebola and Tekmira's other LNP products.

Tekmira believes its LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Tekmira's LNP platform is being utilized in multiple clinical trials by both Tekmira and its partners.

StreetBeat Disclaimer

Distributed by Viestly

D. Medical Issued U.S. Patent No. 8050729

Palm Beach, FL 11/28/11 (StreetBeat) -- D. Medical Industries Ltd. (Nasdaq:DMED), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that it has been granted U.S. Patent No. 8050729, entitled "Devices For Continuous Measurement of Glucose in Body Fluid."

This patent protects innovative technology that allows for the combination of a minimally invasive Continuous Glucose Monitor and an insulin pump on the same "patch." Amongst other features, the technology enables the use of a single access point to both accurately test for blood glucose levels and deliver insulin.

Hezkiah Tsoory, D. Medical's Chief Operating Officer, commented, "The ability to accurately monitor glucose levels and deliver insulin via a single device employing a common insertion point represents a major breakthrough in the delivery of a safe, convenient and minimally invasive experience for insulin pump users. As we continue to develop our product pipeline for commercialization, it is important that the innovations that will define these future products are well protected. This U.S. patent issuance serves again to strengthen D. Medical's already formidable intellectual property estate."

About D. Medical
D. Medical is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. D. Medical has also developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch.

StreetBeat Disclaimer

Distributed by Viestly

LargeCap Stocks to Watch Today

Swan Lake, MS 11/28/2011 (StreetBeat) – AT&T is considering an offer to divest a significantly larger portion of assets than it had initially expected to salvage its $39 billion merger with T-Mobile USA, according to a Bloomberg report.

The exact size of the disposals hasn't been determined, said a person familiar with the plan, but they could be as much as 40% of T-Mobile USA's assets, Bloomberg reported.

The asset sale is an attempt to address the concerns of the Justice Department, which sued to block the takeover on Aug. 31, and the Federal Communications Commission which last week signaled an attempt to block it, Bloomberg said.

Retailers that opened at midnight or earlier on Black Friday, like Wal-Mart , Target , Macy's , Kohl's and Best Buy , saw on average a 24% boost in their conversion (the number of shoppers that actually made a purchase), according to the NPD Group, a consumer research firm.

As shoppers go online Monday to find the best deals -- a day now known as Cyber Monday -- Amazon.com could be a big winner. Cyber Monday 2010 was its peak day last year, the company said.

Ralcorp , the maker of Raisin Bran cereal and other packaged foods, is expected to post fourth-quarter earnings. The report was originally scheduled for Nov. 8, but was delayed pending the completion of a goodwill impairment analysis of the company's Post cereals business.

Analysts expect Ralcorp to earn $1.39 a share in the fourth quarter on revenue of $1.22 billion.

StreetBeat Disclaimer

Distributed by Viestly

Hepatitis C Virus (HCV) Biotech/Pharma Stocks: (OTC: AEMD), (Nasdaq:VRUS), (VRTX)

Palm Beach, FL 11/28/11 (StreetBeat) -- www.InvestorIdeas.com, a global investor research portal for independent investors, issues a biotech/pharma investor snapshot for stocks involved in the treatment of Hepatitis C Virus (HCV). Over 170 million people worldwide are chronically infected with Hepatitis C. The sector made headlines earlier this week as Pharmasset, Inc. (Nasdaq:VRUS ), traded up over 84% on acquisition news.

Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) reported the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

What does this mean for the sector? Are there other potential acquisitions? Some say this acquisition makes Vertex Pharmaceuticals Inc (VRTX ) look relatively cheap.

Pharmasset (Nasdaq:VRUS ) has three clinical-stage product candidates for the treatment of chronic hepatitis C virus (HCV) advancing in trials in various populations. The company’s lead product candidate, PSI-7977, an unpartnered uracil nucleotide analog, has recently been advanced into two Phase 3 studies in genotype 2 and 3 patients. Both studies will utilize 12 weeks of treatment with PSI-7977 in combination with ribavirin. One study will compare this all-oral regimen against 24 weeks of the standard-of-care pegylated interferon/ribavirin in treatment-naïve patients, and the second study will compare the all-oral regimen to placebo in interferon-intolerant/ineligible patients. A third Phase 3 study in genotype 1 patients will be initiated in the second half of 2012, the design of which is dependent on the outcome of Phase 2 studies which are evaluating PSI-7977 in various combinations in genotype 1-infected patients. If successful, this strategy could lead to an initial U.S. regulatory approval of PSI-7977 in 2014. PSI-938, an unpartnered guanosine nucleotide analog, is being tested in a Phase 2b interferon-free trial as monotherapy and in combination with PSI-7977 in subjects with HCV of all viral genotypes. Mericitabine (RG7128), a cytidine nucleoside analog, is partnered with Roche and is being evaluated in three Phase 2b trials. Roche is responsible for all aspects of the development of mericitabine.

Gilead’s research and development portfolio includes seven unique molecules in various stages of clinical development for the treatment of HCV.

James A. Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD) recently updated shareholders on November 16th, “Our Hemopurifier® has demonstrated broad-spectrum capabilities against viral pathogens, including HCV, the human immunodeficiency virus (HIV), and a variety of tested bioterror and pandemic threats. Specific to treating HCV, we previously conducted studies that demonstrated the safe administration of our Hemopurifier® in HCV-infected dialysis patients whose average viral load reductions exceeded 50% during each four-hour treatment. These results were obtained in the absence of any drug therapy.”

Vertex Pharmaceuticals Inc (Nasdaq: VRTX) announced earlier in November its interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (100mg or 400mg), its lead polymerase inhibitor in development, in combination with INCIVEK™ (telaprevir ) tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment. On the basis of the results announced today and previously announced data from other treatment arms of the ZENITH study, Vertex intends to start a Phase 3 study to evaluate a total treatment duration of 12 weeks with this four-drug regimen in treatment naïve and relapser patients with genotype 1 chronic hepatitis C.

More about Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com

StreetBeat Disclaimer

Distributed by Viestly

Oil Prices Rise Above $99 a Barrel in Asia

Swan Lake, MS 11/28/2011 (StreetBeat) – Oil prices rose above $99 a barrel Monday in Asia, taking a cue from gains in stock markets after a strong start to the U.S. holiday shopping season.

Benchmark crude for January delivery was up $2.49 to $99.30 a barrel at midday Bangkok time in electronic trading on the New York Mercantile Exchange. The contract rose 60 cents to settle at $96.77 on Friday.

In London, Brent crude was up $2.13 at $107.99 on the ICE futures exchange.

Oil took its cue from Asian and European stocks, which were mostly higher Monday after record 226 million shoppers visited stores and websites during the four-day U.S. holiday weekend starting on Thanksgiving Day. That was up from 212 million last year, according to early estimates by The National Retail Federation.

Reports that France and Germany might circumvent European bureaucracy to get nations using the euro common currency to comply with strict rules for budget discipline also boosted sentiment.

Crude has fallen from above $103 more than a week ago amid investor concern that Europe's debt crisis will undermine global economic growth and oil demand.

In other Nymex trading, natural gas was up 0.3 cent at $3.545 per 1,000 cubic feet. Heating oil added 4.8 cents to $2.99 a gallon and gasoline rose 6.6 cents to $2.52 a gallon.

StreetBeat Disclaimer

Distributed by Viestly

VelaTel Global Communications (VELA) Stock Chart Analysis

The VELA chart has historically made large moves off the support at a dime. Share have been on a slide back down to that support and the chart is giving hints of another possible bounce off 10 cents.

Distributed by Viestly